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Opiates have long been used as analgesics to relieve
pain associated with various medical conditions. Here,
we evaluated the effect and mechanism of mu opioid
signaling on the intestinal wound healing response and
assessed downstream pathways known to be protective
against intestinal injury. Mice (C57BL/6) were exposed
to 3% dextran sodium sulfate (DSS) for 7 days or 4% DSS
for 5 days followed by 7 days of water. The mu opioid
receptor (MOR)-specific agonist [D-Arg2,Lys4]dermor-
phin-(1,4)-amide (DALDA) and the antagonist cy-
prodime were injected s.c. daily for in vivo studies or
used for in vitro analysis. We found that MOR activation
attenuated DSS-induced histologic and gross intestinal
injury and weight loss; diminished Ifng, Tnf, and Il6
mRNA expression; and promoted intestinal healing dur-
ing recovery. DALDA also enhanced colonocyte prolif-
eration (Ki-67 staining) by 350%. MOR activation in-
creased Stat3 phosphorylation in both DALDA-treated
mice and the CMT-93 cell line. Importantly, DALDA-
induced colonocyte migration was completely ablated
by shStat3 knockdown. Together, this work shows that
MOR activation protects against and enhances recovery
from DSS-induced intestinal injury. This is associated
with an increase in Stat3 activation. Furthermore, Stat3
is required for DALDA-induced colonocyte migration.
Consequently, manipulation of MOR signaling may
represent a novel means to promote mucosal heal-
ing and to maintain intestinal homeostasis after
intestinal injury. (Am J Pathol 2011, 179:673–683; DOI:
10.1016/j.ajpath.2011.04.032)
A critical component of intestinal homeostasis is the pres-
ence of an intestinal mucosal barrier, comprised of a
single monolayer of intestinal epithelial cells (IECs) that
isolates highly antigenic luminal contents from an immu-
nologically rich and underlying stromal compartment.1 Awide body of research has shown that loss of intestinal
barrier function leads to the development of various gas-
trointestinal inflammatory disorders, including inflamma-
tory bowel diseases (IBD).1,2 Conditions leading to an
impaired mucosal barrier function are diverse and in-
clude genetic predisposition, medications (nonsteroidal
anti-inflammatory drugs,3 antibiotics), radiation expo-
sure,4 and ischemic episodes.5 Overt damage to the
epithelial barrier caused by these injuries triggers a host
response, termed restitution/wound healing.6 In this re-
sponse, cells at the edge of the wound undergo a de-
differentiation process and migrate into the wounded
area. They then undergo cytoskeletal rearrangement,7
re-differentiate, and finally re-establish tight junction bar-
riers with their neighboring cells.6 This process does not
require epithelial proliferation, but renewal of cells are
needed to replenish the decreased enterocyte pool after
injury.7 Numerous proliferative signals such as epidermal
growth factor,7 transforming growth factor ,8,9 and cy-
tokines such as IL-2210 are implicated in the mainte-
nance of the mucosal barrier. At the molecular level,
these proliferative signals use various pathways, includ-
ing NF-B, mitogen-activated protein kinase, Stat3, and
PI3K/Akt6 pathways. Identifying factors that engage
these signaling pathways and promote wound healing is
of great therapeutic interest for diseases such as IBD.
Factors that promote wound healing include the var-
ious neuropeptides produced by the enteric nervous
system. Of strong relevance to IBD, several neuropep-
tides modulate immune cell function and could conse-
quently affect the development of intestinal inflamma-
tion.11 Opioids are a class of neuropeptides that have
traditionally been used as analgesics; however,
emerging literature associates this class of neuropep-
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Vertebrates traditionally express three types of opioid
receptors: mu, delta, and kappa, all of which are G-
protein– coupled receptors that preferentially bind to Gi
proteins. Binding of ligand to these receptors leads to
the prototypical inactivation of neural pain fibers.13–15
Interestingly, recent studies have shown opioids to
protect against ischemia/reperfusion-induced cardiac
injury.16,17 Furthermore, the peripheral mu-specific ag-
onist [D-Arg2,Lys4]dermorphin-(1,4)-amide (DALDA)18
reduces inflammation in two experimental models of mu-
rine colitis: 2,4,6-trinitrobenzene sulfonic acid (TNBS)
and adoptive transfer of CD45RBhiCD4 T cells.19 Con-
versely, experimental colitis is exacerbated in mu opioid
receptor (MOR) knockout mice,19 and MOR expression is
up-regulated in mucosal samples from human patients
with IBD compared with controls.20 Together, these data
implicate an important role for MOR signaling in regulat-
ing gut homeostasis. Although these studies have not
fully addressed the mechanism by which MOR signaling
ameliorates intestinal inflammation, it appears that down-
regulation of cytokine production and modulation of T-cell
function contributes to MOR’s beneficial effect.
On the basis of its beneficial effect in other models of
colitis,19 as well as in ischemia-induced cardiac in-
jury,16,17 we hypothesized that MOR signaling is cytopro-
tective in the context of intestinal barrier damage. With
the use of a chemical model of acute injury and wound
healing that is independent of T and B cells,21 we ob-
served that the mu opioid agonist DALDA protects
against dextran sodium sulfate (DSS)-induced intestinal
injury and promotes healing through activation of Stat3
and induction of cytoprotective factors regulated in part
by Stat3. Our findings suggest that MOR agonists could
represent a novel means to modulate tissue injury and
enhance intestinal restitution and proliferation.
Materials and Methods
DSS-Induced Acute Injury
Wild-type and transgenic NF-BEGFP reporter mice
(C57BL/6 background) were maintained in standard
housing cages in specific pathogen-free conditions. Mice
(N  7), were given 3% DSS (MP Biomedicals, Aurora,
OH) in their drinking water for 7 days, whereas control
mice received water alone. Water consumption was com-
parable between the different experimental groups.
Throughout DSS administration, vehicle (10% dimethyl
sulfoxide/90% saline), the peripheral (does not cross the
blood-brain barrier) MOR agonist DALDA18 (100% saline,
50 g/kg; US Biological, Swampscott, MA), or the MOR
antagonist cyprodime22 (10% dimethyl sulfoxide /90%
saline, 10 mg/kg; Tocris Bioscience, Ellisville, MI) was
injected s.c. daily on the mid-dorsal surface of the mice.
Mice were monitored daily for weight loss and visible
signs of rectal bleeding. Occult bleeding was evaluated
at day 4 of the experiment (Hemoccult; Beckmann
Coulter Inc., Fullerton, CA), in accordance with internal
pilot studies that showed occult bleeding to be reliablyobservable in this model from day 4 onward. Clinical
score, assessing weight loss, occult blood, and stool
consistency were calculated as previously described.23
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
North Carolina at Chapel Hill.
DSS Recovery Studies
C57BL/6 mice (N  6) were administered 4% DSS in their
drinking water for 5 days, followed by water for a recovery
period of 7 days. DALDA or vehicle was injected s.c.
daily during the water recovery phase, as described ear-
lier. Occult bleeding was evaluated at day 12. Mice were
euthanized at days 8 and 12. Colonoscopies were per-
formed as described previously,24 on days 5, 8, and 12.
Sample Collection and Histologic Evaluation
Mice were sacrificed at the indicated time points by CO2
asphyxiation followed by cervical separation. The colon
was dissected and flushed with ice-cold PBS, longitudi-
nally splayed, Swiss rolled, fixed in 10% formalin for 24
hours, and then embedded in paraffin. Colitis severity
was evaluated with H&E-stained sections by a blinded
investigator on a scale from 0 to 40, as described previ-
ously.2,25,26
Immunohistochemistry (IHC) staining for pStat3(Y705) (Cell
Signaling Technology Inc., Beverly, MA) was performed ac-
cording to the manufacturer’s specifications at a 1:50 dilution
as previously described.24 Ki-67 staining was performed as
previously described.24 All sections were counterstained with
hematoxylin. Two different sections (per animal), approxi-
mately 200 m apart, were assessed for staining, and repre-
sentative images are shown.
For protein analysis, distal colons were dissected,
flushed with ice-cold PBS, and homogenized for 15 sec-
onds with a polytron (IKA Works Inc., Wilmington, NC) in
cold RIPA buffer containing proteinase inhibitors (Com-
plete Mini; Roche Diagnostics GmbH, Penzberg, Ger-
many) and phosphatase inhibitor cocktail no. 2 at a 1:100
dilution (Sigma-Aldrich, St. Louis, MO). After incubation
at 4°C for 30 minutes, samples were sonicated and
cleared. Lysates were then diluted 1:1 with 2 Laemmli
buffer.
Confocal Analysis of EGFP Expression
Colons were fixed in 4% paraformaldehyde for 40 min-
utes at room temperature and permeabilized in 2% Triton
X-100 for 18 to 22 hours at 4°C. Tissues were rinsed in 1
PBS, counterstained with propidium iodide (Molecular
Probes, Eugene, OR) for 30 minutes, and then placed in
custom imaging chambers and immersed in Focus Clear
(Cedar Lane Labs, Burlington, NC). Tissues were imaged
with an Olympus Fluoview FV1000MPE microscope, with
a 25 long-working distance water immersion objective.
Enhanced green fluorescent protein (EGFP) was excited
with a 495-nm laser, and propidium iodide was excited
with a 559-nm laser. Tissue was imaged from the surface
to a depth of 120 m with a standard scale for laser
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maintained between samples. Images were analyzed
with BioImage XD and Imaris (Bitplane AG, Zurich, Swit-
zerland).
CMT-93 Cell Culture and Stimulation
Murine rectal carcinoma cells (passage 33 to 59; Amer-
ican Type Culture Collection, Manassas, VA) were cul-
tured in Dulbecco’s modified Eagle’s medium-high glu-
cose as described previously.27 Cells were starved for 18
to 22 hours in Opti-MEM and then treated with DALDA
(10 mol/L) or naloxone (10 mmol/L; Sigma-Aldrich) for
the times indicated. Cells were directly lysed in 1 Laem-
mli buffer, and protein concentration was measured with
Bio-Rad quantification assay (Bio-Rad Laboratories, Her-
cules, CA).
Luciferase Assays
CMT-93 cells were infected with Ad5B-Luc vector28 for
12 hours in Opti-MEM and then were stimulated with
lipopolysaccharide (LPS; 10 g/mL) in the presence or
absence of 10 mol/L DALDA. Luciferase assay was
performed on a Monolight 2010 luminometer for 20 sec-
onds (Analytical Luminescence, San Diego, CA).
Western Blot Analysis
Proteins (30 g) were separated with the use of 10%
SDS-PAGE and transferred to nitrocellulose membranes
and then probed with antibodies to pStat3(Tyr705) (1:
2000), extracellular signal-related kinase 1 and 2
(ERK1/2; 1:1000), pERK1/2 (1:2000; Cell Signaling Tech-
nology Inc.), Stat3 (1:1000; Santa Cruz Biotechnologies,
Santa Cruz, CA), and -actin (1:1000; MP Biomedical,
Solon, OH) and were used with 5% milk in Tris-buffered
saline (TBS)-Tween (0.1%) or 5% bovine serum albumin
in TBS-Tween (0.1%; for Cell Signaling Technology Inc.
antibodies), followed by the appropriate horseradish per-
oxidase–conjugated secondary antibody (GE Health-
care, Piscataway, NJ) and detected by chemilumines-
cence. Densitometry analysis for pStat3 was performed
with NIH ImageJ software version 1.43 (http://rsbweb.nih.
gov/ij), to determine the ratio of pStat3 to Stat3, when
indicated.
Immunofluorescence
CMT-93 cells were grown to 50% confluence in Opti-
MEM media on glass cover slides. Cells were fixed in
ice-cold methanol, blocked with normal goat serum, and
incubated with 1:100 anti-pStat3(Y705) (Cell Signaling
Technology Inc.) followed by anti-rabbit tetramethylrhod-
amine isothiocyanate (1:100; Jackson Immunoresearch
Laboratories, West Grove, PA) for 30 minutes. Cells were
then counterstained with Hoechst dye and mounted with
Fluoromount-G (Southern Biotech, Birmingham, AL). Im-
ages were captured with a Zeiss LSM 710 confocal mi-
croscope (Zeiss, Jena, Germany).RNA Isolation and Real-Time PCR
RNA isolation from colonic tissues and CMT-93 cells and
subsequent mRNA analysis were performed as previ-
ously described,24 using an ABI Prism HT7700. Specific-
ity and linearity of amplification for each primer set were
determined by melting curve analysis and calculation of
the slope from serial diluted samples. Relative fold
changes were determined with the CT calculation
method. Values were normalized to the internal control
glyceraldehyde-3-phosphate dehydrogenase. Primers




and 5=-AGGCCACAGGTATTTTGTCG-3=), GAPDH (5=-
GGTGAAGGTCGGAGTCAACGGA-3= and 5=-GAGGGA-
TCTCGCTCCTGGAAGA-3=),29 and Cox2 (Ptgs2) (5=-TG-






















































































































































































Figure 1. MOR activation protects against DSS-induced intestinal injury.
Mice were given 3% DSS for 7 days concurrent with opioid treatment. DALDA
(50 g/kg), cyprodime (10 mg/kg), or vehicle was injected s.c. daily. All
graphs depict mean  SEM. A: Percentage of weight loss from starting
weight. N  7 for all groups. P  0.001  2-way analysis of variance between
treatment groups and over time; P  0.05 for DALDA-treated versus vehicle-
treated at day 7. B: Clinical score. N  7 for all groups. P  0.01 for DALDA-
treated versus vehicle-treated. C: Histologic score. N  5 for all groups. D: Crypt
damage score. N  4 for all groups. E: Representative H&E photomicrographs.
Scale bar  100 m for all sections. F: Fold change Tnf and Il6 distal colonic
mRNA expression. N  4 for all groups. *P  0.05, **P  0.01.
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CCTTCTCTCCT-3=).30 Cyclin D (Ccnd1), Ifng, Myc, and
Reg3b are QuantiTect primers (Qiagen, Valencia, CA).
Migration and Proliferation Assays
Migration assays were performed as described previ-
ously.31 Briefly, CMT-93 cells were plated to confluence
in Opti-MEM and then were scratched with a P1000 pi-
pette tip. DALDA (10 mol/L) in PBS or PBS alone was
then immediately added. Four different regions per plate
were demarked, and images were taken at the specified
time points with the use of an Olympus IX7 microscope
(Center Valley, PA). Images were analyzed with NIH Im-
ageJ software. Each experiment was measured at four
individual points and was repeated independently at
least two times.
Reproductive proliferation assays32 were performed
by plating CMT-93 cells at a known cellular density, and,
2 hours after plating, cells were switched to 1% serum
media and stimulated for 8 hours with 10 mol/L DALDA
in PBS or PBS alone. Cells were then trypsinized and
counted with the use of trypan blue. Each plate was
counted four different times, and the experiment was
repeated independently at least two times.
shRNA Knockdown
A stable shStat3 knockdown CMT-93 cell line was
created with a lentivirus provided by the University of
North Carolina at Chapel Hill Lentiviral shRNA (short hair-
pin RNA) Core with a mixture of four different shStat3
constructs. Open Biosystems TC1 library numbers
TCRN0000071453 to TCRN0000071457 were used
(pLKO.1 vector).33 Control shRNA virus SHC-002 (Sigma-
Aldrich) was used to create a stable control knockdown
line. Cells were maintained in selection media containing
2 g/mL puromycin, to which the lentiviral vectors con-
ferred resistance but completely killed uninfected cells.
Statistical Analyses
Statistical analyses were performed with GraphPad Prism
version 5.0a (GraphPad, La Jolla, CA). Comparisons of
weight between mouse groups and over time were done
with a two-way analysis of variance. Weight posttests and
further comparisons made between mice were analyzed
with a Mann-Whitney U-test at a 95% confidence interval.
In vitro data and Ki-67 and pStat3 cell counting were
compared with Student’s t-tests, at a 95% confidence
interval. All graphs depict mean  SEM. Experiments
were considered statistically significant if P  0.05.
Results
DALDA Ameliorates DSS-Induced Intestinal
Injury
To investigate the effect of MOR signaling in intestinal
injury response, we used the mu-specific agonist DALDAin a DSS model of acute intestinal injury. Mice were ad-
ministered 3% DSS for 7 days, along with sterile s.c.
injections of saline (vehicle), mu-specific agonist DALDA
(50 g/kg),18 or the mu-specific antagonist cyprodime
(10 mg/kg).22 We found that DALDA significantly attenu-
ated DSS-induced weight loss (Figure 1A). Clinical
scores, which factors in weight loss, diarrhea, and bloody
stool, showed that DALDA-treated mice displayed a sig-
nificant reduction in disease compared with untreated
mice (mean, 5.92 versus 3.93; P  0.01), whereas MOR
antagonism exacerbated disease (mean, 5.92 versus
7.92; P  0.01; Figure 1B). Histologic scores (Figure 1C)
showed that DALDA significantly reduced intestinal in-
flammation compared with vehicle-treated mice (mean,
24.2 to 10.8; P  0.01), whereas cyprodime worsened
inflammation (mean, 24.2 to 33.5; P  0.05). In addition,
DSS-induced histologic crypt damage was attenuated by
DALDA treatment, whereas cyprodime exacerbated
damage (Figure 1D). The extent of the pathologic
changes of DALDA and cyprodime on DSS-induced in-
testinal injury is shown in Figure 1E.
After establishing that MOR activation protected
against DSS-induced injury, we assessed the effects of
DALDA on inflammatory cytokines. We found that DALDA
significantly reduced colonic Tnf and Il6 mRNA expres-
sion (Figure 1F). Because these cytokines are induced in
part through immune-derived NF-B signaling during ex-
perimental colitis,34 we next explored the effect of daily
s.c. injections of DALDA on NF-B activity with the use of
fresh-fixed tissue sections obtained from NF-BEGFP re-
porter mice and confocal microscopy imaging. As previ-
ously reported, EGFP expression in the lamina propria
increased in DSS-exposed NF-BEGFP reporter mice.29,35
Interestingly, lamina propria-derived EGFP expression
(NF-B activity) was strongly reduced in DALDA-treated
mice (see Supplemental Figure S1 at http://ajp.amjpathol.
org). Moreover, DALDA failed to block LPS-induced
NF-B transcriptional activity in CMT-93 cells (see Sup-
plemental Figure S1 at http://ajp.amjpathol.org). These
findings indicate that DALDA protects against DSS-
induced acute intestinal injury in mice and is associated
with reduced immune cell-derived NF-B activation and
pro-inflammatory gene expression without directly inhib-
iting NF-B signaling.
MOR Activation Enhances Recovery from
DSS-Induced Intestinal Injury
Because wound healing is a critical process during
tissue repair, we evaluated the effect of DALDA on
recovery from DSS-induced intestinal injury. Mice were
administered 4% DSS for 5 days, followed by 7 days of
s.c. injections of saline or 50 g/kg DALDA. Gross
mucosal damage visualized by colonoscopy showed
attenuation of macroscopic lesions by day 7 in DALDA-
treated mice (Figure 2B). Furthermore, DALDA en-
hanced weight loss recovery, and DALDA-treated mice
returned to near-normal weight by day 7 of the recov-
ery phase (Figure 2A). DALDA similarly reduced clini-
cal scores after 7 days of recovery (mean, 5.3 versus
mRNA accumulation was determined by RT-PCR. N  4 for all groups. ns, not
significant. *P  0.05, **P  0.01.
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were noticeably lower after only 3 days of therapy
(mean, 29.2 versus 15.6, P  0.01 at day 3; 23.2 versus
11.3, P  0.01 at day 7; Figure 2D), with initial improve-
ments associated with decreased crypt damage
(mean, 9.7 versus 3.7; P  0.05 at day 3, Figure 2E). In
accordance with histologic and clinical decreases in
disease, Tnf, Il6, Il1b, and Ifng mRNA levels were sig-
nificantly reduced in DALDA-treated than in vehicle-
treated mice (Figure 2F). These findings indicate that
DALDA protects against DSS-induced intestinal injury
and promotes wound healing.
DALDA Enhances Colonocyte Proliferation and
Stat3 Activation in Vivo
Because proliferation is an important feature of the heal-
ing response that occurs after migration/restitution, we
measured proliferation in DALDA-treated mice by Ki-67
staining. We observed a modest 38% increase in prolif-
erative activity (P  0.01) in DALDA-treated mice com-
pared with control (Figure 3). Importantly, proliferation









































Figure 3. Enhanced colonocyte proliferation in DALDA-treated mice. All
graphs depict mean  SEM. A: Representative photomicrographs. Scale














































































































































































































































































































































































Figure 2. MOR activation enhances recovery from DSS-induced intestinal
injury. Mice were administered 4% DSS for 5 days, followed by 7 days of
water recovery concurrent with treatment: 50 g/kg DALDA or vehicle was
injected s.c. daily. All graphs depict mean  SEM. A: Percentage of weight
loss from starting weight. N  6 for all groups. B: Representative colonos-
copies for each group on the final day of the experiment. C: Clinical score.
N  6 for all groups. D: Histologic score. N  4 for all groups. E: Crypt
damage score. N  4 for all groups. F: Fold change Tnf, Il6, Il1b, and Ifngmultiple fields of view. N  4 for all groups except DALDA alone, for which
N  3. *P  0.05, **P  0.01.
678 Goldsmith et al
AJP August 2011, Vol. 179, No. 2exposed, DALDA-treated mice compared with DSS alone
(Figure 3).
Because Stat3 signaling is also a critical proliferative
response in the DSS acute model of intestinal injury,10 we
next determined the effect of MOR agonists on Stat3
activation. Compared with untreated controls, DSS-ex-
posed mice showed a fivefold increase in colonic pStat3.
DALDA therapy alongside DSS injury increased pStat3
10-fold (P  0.001) over that of untreated controls (Figure
4A); surprisingly, mice given DALDA alone without DSS
injury did not have increased levels of pStat3 over con-
trols (N  4; data not shown), suggesting that Stat3
activation by MOR is tightly regulated and that MOR-
mediated activation occurs only in the presence of injury.
IHC indicated that DALDA-induced Stat3 phosphoryla-
tion appears predominately in colonocytes (Figure 4, B
and C), resulting in a 2.7-fold increase in pStat3-positive
colonocytes per 20 crypts (P  0.05) in DALDA-treated
compared with vehicle-treated mice exposed to DSS.
We next assessed the expression of cytoprotective
genes regulated in part by Stat3, using real-time PCR.
As anticipated, DALDA significantly enhanced expres-
sion of cyclooxygenase 2 (Ptgs2), Myc, Reg3b, and






































































































































tgcompared with vehicle-treated mice (Figure 4D). These
specific cytoprotective genes were selected because
their expression decreased in DSS-exposed Stat3IEC
mice compared with wild-type mice,10 showing that
they are regulated by Stat3 in colonocytes.
DALDA Enhances Stat3 Phosphorylation
in Vitro
To gain more insight into the role of Stat3 in MOR-medi-
ated protective effect, we used an in vitro cell system.
CMT-93 cells were exposed to DALDA (10 mol/L) for 1
hour after which time Stat3 phosphorylation was mea-
sured by Western blot analysis. Densitometric analysis
showed that pStat3 levels increased by approximately
threefold in DALDA-treated cells compared with unstimu-
lated cells (P  0.05 compared with an assumption of a
zerofold change; Figure 5A). In addition, immunofluores-
cence assays showed an increased level of pStat3 in
DALDA-treated cells compared with unstimulated cells
(Figure 5B). We determined whether the general opioid
antagonist naloxone could inhibit DALDA-induced pStat3
























Figure 4. DALDA enhances Stat3 activation in
DSS-induced intestinal injury. Mice were admin-
istered 3% DSS  vehicle or 3% DSS  DALDA
(50 g/kg, injected s.c. daily) for 7 days. All
graphs depict mean  SEM. A: Levels of Stat3
phosphorylation (Y705) in distal colonic tissue
measured by Western blot analysis. Relative level
of pStat3 over total Stat3 was determined by den-
sitometry. Representative of four individual mice.
B and C: pStat3 IHC analysis. Representative im-
ages of four mice per group. Scale bars  100 m
in all images. White boxes outline higher mag-
nification images of each section. Bar graph
shows pStat3-positive colonocytes per 20 crypts.
D: Expression of Stat3-dependent genes (Ptgs2,
Myc, Reg3b, Ccnd1) in distal colonic tissue. N 












































Activation of Stat3-dependent genes (Ptgs2, Myc, Ccnd1, Reg3b). N  4 for both
groups, in two independent experiments. *P  0.05, **P  0.01, and ***P  0.001.
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lation. We then investigated the effect of DALDA on cy-
toprotective genes regulated in part by Stat3 with the
use of real-time PCR. Expression of Myc, cyclooxygen-
ase 2 (Ptgs2), cyclin D (Ccnd1), and Reg3b mRNA
were significantly induced in DALDA-stimulated
CMT-93 cells (Figure 5C). These studies indicate that
colonocytes respond to a MOR agonist by activating
Stat3 signaling and downstream cytoprotective medi-
ators.
ERK phosphorylation is a well-established downstream
consequence of Gi-coupled G protein-coupled receptor
activation and a classic effector of MOR activation.36 We
detected ERK1/2 phosphorylation in the distal colonic
tissue of DALDA-treated mice and in DALDA-stimulated
CMT-93 cells (Figure 6, A and C). To confirm the speci-
ficity of DALDA-induced ERK1/2 phosphorylation,
CMT-93 cells were pretreated (30 minutes) with the MOR
competitive antagonist naloxone (10 mmol/L) and then
stimulated with DALDA. Interestingly, levels of pERK1/2
are slightly augmented in naloxone-treated cells, a phe-
nomenon previously reported.37,38 Importantly, naloxone
attenuated DALDA-induced pERK1/2 in CMT-93 cells
(Figure 6B).
DALDA Enhances Colonocyte Migration in a
Stat3-Dependent Manner
Because DALDA promoted proliferation in vivo and acti-
vated protective/proliferative signaling in vitro, we next
explored the effect of MOR activation on cellular restitu-
tion/migration with the use of an in vitro wound healing/
scratch-assay model. Immediately after wounding, cells
were incubated with DALDA (10 mol/L), and 8 hours
later the distance migrated into the scratch was mea-
sured with ImageJ software. Migration increased by 67%
(P  0.001) in DALDA-treated compared with untreated
cells (Figure 7, A and B). Furthermore, reproductive cel-
lular proliferation assays showed that DALDA enhanced
CMT-93 proliferation by 45% during the same time period
(Figure 7C; P  0.05). Because DALDA enhanced Stat3
phosphorylation in vivo and in vitro, we determined the
functional effect of this signaling event on CMT-93 migra-
tion with the use of a shRNA knockdown approach.
CMT-93 cells were infected with a lentiviral vector con-
taining shStat3 and a puromycin-resistance gene, allow-
ing for the selection and maintenance of a stable knock-
down line. Stat3 expression was efficiently inhibited in
shStat3-infected cells compared with scramble controls
(Figure 7D). Moreover, DALDA-induced pStat3 was
strongly blocked in shStat3-infected cells compared with
the short hairpin control (Figure 7E). Most importantly,
DALDA-induced cellular migration was completely abro-
gated in shStat3-infected cells compared with control-
infected cells (Figure 7F). These findings show that
DALDA drives colonocyte migration in a Stat3-dependent
manner and, combined with our in vivo studies, show that
MOR activation enhances intestinal wound healing by


























































































































































Figure 5. DALDA induces Stat3 phosphorylation in CMT-93 cells. A–C: CMT-93
cells were treated for 1 hour with 10 mol/L DALDA or vehicle. A: Western blot
analysis and densitometry compare pStat3 with Stat3 within the same sample.
Representative of eight independent experiments. B: pStat3 immunofluorescence
staining, representative of triplicate samples, from two independent experiments. C:ation, in a manner involving Stat3 signaling.
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As a result of their ability to promote intestinal repair,
increasing clinical interest has focused on the use of
trophic factors to treat diseases associated with chronic
epithelial injury such as IBD.2,39,40 Here, we have dem-
onstrated that peripheral activation of the mu opioid path-
way protects against DSS-induced intestinal injury and
enhances wound healing. We have shown that the MOR-
specific agonist DALDA activates proliferative signaling
in the intestine, a response associated with enhanced
colonocyte-derived Stat3 activation and induction of cy-
toprotective genes. In contrast, the MOR-specific antag-
onist cyprodime worsens DSS-induced intestinal injury,
suggesting that this opioid pathway plays an essential
role in the intestinal wound-healing response. Interest-
ingly, previous reports have shown that low-dose therapy
of the nonspecific opioid antagonist naltrexone protects
against both DSS-induced injury in mice and ameliorates
Crohn’s disease in a small, open-label patient study.41,42
In these studies, naltrexone was deliberately adminis-
tered at levels below the dose needed to pharmacolog-
ically block receptor function. Because the MOR-specific
antagonist cyprodime exacerbates DSS-induced colitis,
it is probable that low-dose naltrexone therapy acts to
potentiate endogenous opiate signaling.41–43 However,
such a mechanism remains controversial and has never
been truly established.
Our work provides significant new insights into the
mechanisms behind DALDA-mediated amelioration of in-
testinal injury and inflammation. Chronic opiate adminis-
tration is known to be immunosuppressive clinically and
Figure 6. DALDA induces ERK1/2 phosphorylation by an opioid-dependent
pathway. A: Western blot analysis for pERK1/2 in CMT-93 cells stimulated
with 10 mol/L DALDA for 0 to 60 minutes. Representative of three individ-
ual experiments. B: Western blot analysis for pStat3 and pERK1/2 in CMT-93
cells stimulated with DALDA for 1 hour with or without 30-minute pretreat-
ment with 1 mmol/L of the opioid antagonist naloxone. Representative of
three individual experiments. C: DALDA induces colonic ERK1/2 phosphor-
ylation in vivo. Western blot analysis for pERK1/2 from distal colonic protein
extracts from individual control mice or mice injected with 50 g/kg DALDA
daily s.c. for 7 days.specifically inhibits T-cell, B-cell, and natural killer-cellfunction.11,44,45 Moreover, DALDA has been shown to be
protective in two T-cell driven models of murine colitis:
the TNBS and adoptive transfer of CD45RBhiCD4 T-cell
models.19 This implies that MOR-mediated immunosup-
pression may provide a potential mechanism for MOR-
mediated protection from intestinal injury. However, DSS-
induced acute colitis has been shown to be independent
of T cells, B cells, and natural killer cells21; hence,
DALDA cannot be solely operating through inhibition of
adaptive immune responses. Although we observed de-
creased activation of NF-B (EGFP expression) and in-
flammatory gene expression in DALDA-treated mice,
these observations are probably a secondary effect of
the drug because genetic ablation of IEC-derived NF-B
signaling46–50 and blockade of the pathway29,35,51 are
both known to exacerbate injury response in the intestine.
In addition, in vitro NF-B transcriptional activity in IECs
was not inhibited by DALDA treatment (data not shown).
We show that DALDA operates in part through the
enhancement of wound healing and cellular proliferation
in response to DSS-induced epithelial damage. Indeed,
an early effect of DALDA therapy is improvement of the
crypt damage score and enhanced epithelial proliferative
responses (Ki-67 staining). These observations suggest
that DALDA acts by enhancing both epithelial prolifera-
tion and damage repair responses. This concurs with our
in vitro data showing that DALDA enhanced IEC prolifer-
ation/migration after wounding. We postulate that the en-
hanced wound healing afforded by DALDA limits luminal
antigenic activation of lamina propria immune cells
(NF-B activation, cytokine expression) and inflammation
through epithelial restitution/migration and enhanced
colonocyte proliferation.
The novel finding that DALDA induced IEC Stat3 phos-
phorylation both in vivo and in vitro is particularly relevant
to the wound-healing response. IEC-derived Stat3 signal-
ing has been shown to confer protective responses
against DSS-induced intestinal injury through the promo-
tion of wound-healing responses10,52; furthermore, Stat3
signaling is a known driver of enterocyte prolifera-
tion.52,53 IHC staining showed that colonocytes are the
predominant cells exhibiting pStat3 in DALDA-treated,
DSS-exposed mice. DALDA enhanced expression of cy-
toprotective genes (Reg3b, Ccnd1, Cox2, myc) that are
lost in Stat3IEC mice known to be sensitive to DSS
injury.10 The up-regulation of these genes only in the
presence of DALDA suggests that, although DSS alone
can up-regulate colonocyte Stat3 activation to an extent,
only the presence of DALDA and subsequent exogenous
MOR signaling is to generate protective responses,
through higher elevated pStat3 levels and increased cy-
toprotective gene expression and proliferation (Ki-67
staining).
Our gene expression observations could also be reca-
pitulated in vitro with CMT-93 colonocytes, whereby we
also saw that DALDA increases pStat3 levels in CMT-93
cells and enhances cellular migration in response to a
wound, as well as enhances cellular proliferation. Knock-
down of Stat3 showed the importance of Stat3 signaling
in DALDA-mediated enhanced migration, because this
CMT-93
ts; N 
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cells compared with control.
These observations strongly suggest that DALDA pro-
motes protective function in the intestine through a mech-
anism involving Stat3 activation. Although IECs are the
predominant cells exhibiting pStat3 in response to
DALDA treatment, it is unclear whether these cells are the
main target of the opioid. Tissue-specific MOR gene de-
letion will be necessary to evaluate the cellular compart-
ment implicated in DALDA-induced protective response.
In addition, although Stat3IEC mice are available, pre-
vious work has shown that these mice are extremely
sensitive to DSS colitis and have severe defects in epi-
thelial restitution,10 making exploring the role of DALDA
on such a sensitive background untenable.
ERK1/2 is a canonical downstream effector of Gi-cou-
pled signaling and represents a classic read-out of opi-
oid signaling. Interestingly, although we observed persis-
tent in vivo activation of ERK1/2 in DALDA-injected mice,
Stat3 phosphorylation was observed only in the context of
DALDA administration during an injury response. This
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Figure 7. DALDA enhances colonocyte migration in a Stat3-dependent man
vehicle. Migration was observed over a 24-hour period. A: Representative ph
100 m. B: Quantification of migration distance after 8 hours. Mean results
cellular proliferation assays. CMT-93 cells were treated with 10 mol/L DALD
of two independent experiments; N  4 for each experiment. D–F: Cells we
shRNA (shScramble). D: Western blot analysis representative of three indepe
show reduced DALDA-induced Stat3 phosphorylation in shStat3-infected
migration over an 8-hour period. Representative of two separate experimensuggests that MOR-mediated Stat3-driven proliferation invivo is tightly regulated, and activation depends on the
injury status of the epithelium. A previous study has iden-
tified IL-22 as a key cytokine involved in DSS-induced
pStat3 and injury response.10 Interestingly, we observed
enhanced colonic IL-22 mRNA expression in DALDA-
treated, DSS-exposed mice (J.R.G. and C.J., unpub-
lished observation). Further studies will be required
before establishing the functional role of IL-22 in DALDA-
mediated cytoprotective effect in the intestine.
Our work highlights a potential new therapeutic class
of compounds for the treatment of diseases involving
intestinal barrier damage, including ischemic injury, radi-
ation-induced damage, and IBD. One could envision the
use of opioids as an adjunct therapy in IBD by helping to
induce or maintain remission through promoting re-epi-
thelialization of the intestine. In particular, opioids could
be used as an adjunct in helping to induce remission in
IBD by lowering the amount of prednisone needed or as
a mainline therapy in steroid-refractory patients. Use of
opioids for IBD therapy needs to be pursued cautiously,
















































































CMT-93 monolayers were scratched and treated with 10 mol/L DALDA or
graphs of cell migration. Shaded bar shows initial wound area. Scale bar 
e3 independent experiments; N  4 for each experiment. C: Reproductive
hicle for 8 hours, and direct cell quantification was performed. Mean results
ed with a shStat3 lentivirus to reduce Stat3 expression or control scrambled
periments show Stat3 knockdown in shStat3 cells. E: Western blot analyses
cells. Representative of two individual experiments. F: Quantification of








ndent exact through increased colonocyte proliferation, and pa-
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AJP August 2011, Vol. 179, No. 2tients with IBD already have an increased risk of malig-
nant transformation. Consequently, MOR-targeted ther-
apy would probably be best suited toward short-term use
for remission induction, similar to prednisone. Other, non-
IBD applications could include enhancing recovery from
radiotherapy-induced injury and use as a gut-saving
agent in cases of ischemic injury.
In summary, this report establishes mu-specific opi-
oids as promoters of colonocyte migration/restitution and
proliferation in the intestine involving the activation of
Stat3-dependent pathways. Because opioids are already
available on the market and have well-known safety pro-
files, this class of compounds could represent a novel
therapeutic approach to gastrointestinal therapy, once
clinical trials validate their beneficial effect in patients.
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